Identification of the lncRNA signature related to Sorafenib effectiveness in liver cancer cells.

• Parras Martínez, Ester ^[2] ; de la Cruz Ojeda, Patricia ^[3] ; Cahuana Macedo, Gladys Margot ^[1] ; Muntané Relat, Jordi ^[3]
  1. [1] Universidad Pablo de Olavide

     Universidad Pablo de Olavide

     Sevilla, España

     
  2. [2] (1) Institute of Biomedicine of Seville (IBiS), "Oncological Surgery. Cell therapy and organ transplantation", University Hospital "Virgen del Rocío"/CSIC/University of Seville.
  3. [3] (1) Institute of Biomedicine of Seville (IBiS), "Oncological Surgery. Cell therapy and organ transplantation", University Hospital "Virgen del Rocío"/CSIC/University of Seville. (2) Department of Medical Physiology and Biophysics, University of Seville. (3) Centre for Biomedical Research in Liver and Digestive Diseases (CIBERehd), Madrid.

  Mostrar afiliaciones +
• Localización: Biosaia: Revista de los másteres de Biotecnología Sanitaria y Biotecnología Ambiental, Industrial y Alimentaria, ISSN-e 2254-3821, Nº. 13, 2024
• Idioma: español
• Enlaces
  • Texto completo
• Resumen

  • Hepatocellular carcinoma is the most common form of primary liver cancer being globally recognized as the fourthcause of cancer-related death [1]. The impact of risk factors on HCC has a variable geographic distribution, includinghepatitis C (HCV) and B (HBV) virus infection, alcohol, aflatoxin B1, metabolic-associated steatotic liver disease(MASLD), tobacco and congenital diseases. Patients with advanced stage of HCC who lack preserved liver function,as well as vascular disorders and high blood pressure cannot benefit from the first-line systemic therapies(Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab), and they are recommended to receive Sorafenib.Sorafenib is an orally administered multityrosine kinase inhibitor approved by the FDA for the treatment of HCC in2008 [2, 3]. Among non-coding RNA, miRNAs, lncRNAs and circRNAs have been related to the initiation, progressionand metastasis in HCC [4]. The group has recently shown that miR-512-3p exerts oncogenic role, and miR-200c-3pexert antitumoral properties under Sorafenib treatment in vitro, in vivo and in two independent cohorts of patients [5].In this study we focus on lncRNA, a ncRNA molecule of more than 200 nucleotides. LncRNAs carry out manybiological processes, including the regulation of proliferation, invasion, differentiation and metastasis. LncRNA alsoregulate gene transcription and translation by modifying the microRNA and mRNA signature in cells [6]. We haveidentified the lncRNA signature in response to Sorafenib in two liver cancer cell lines. In silico analysis of RNAseqdata highlighted the differential expression of 11 Sorafenib-regulated lncRNAs in both cell lines. In vitro functionalstudy validated the results obtained in silico. Sorafenib decreased the expression of 9 lncRNAs and increased theexpression of 1 lncRNA. We will carry out specific experimental approaches to determine the functional role of theseselected lncRNAs in cell invasion and migration. The final outcome of the project would be to determine whether thelncRNA signature might be a new biomarker of disease prognosis and treatment responsiveness.